Request for Proposals (RFP) Increasing Rates of BRCA Testing in Patients with Breast Cancer

Funding Agency:
Pfizer Inc.

Pfizer Inc. and the Association of Community Cancer Centers (ACCC) are collaborating to offer community cancer centers a grant opportunity for quality improvement initiatives focused on increasing the rates of BRCA testing for patients with either early or metastatic breast cancer. We are looking for community hospital-based programs and physician group practices that are interested in integrating BRCA mutation testing as a part of the care plan for all breast cancer patients and utilizing the results of the genetic test to help inform treatment plans for their patients. Only ACCC member institutions are eligible to apply.

The mission of Pfizer Independent Grants for Learning & Change (IGLC) is to partner with the global health care community to improve patient outcomes in areas of mutual interest through support of measurable learning and change strategies. “Independent” means that the projects funded by Pfizer are the full responsibility of the recipient organization. Pfizer has no influence over any aspect of the projects and only asks for reports about the results and the impact of the projects in order to share them publicly. 

This Request for Proposals (RFP) is being issued by both organizations. ACCC is the lead organization for review and evaluation of applications. A review committee, led by ACCC, will make decisions on which proposals will receive funding. Grant funding will be provided by Pfizer Inc. Collectively, $1.5 million is available to fund at least ten proposals. 

ACCC and Pfizer encourage proposals for quality improvement initiatives focused on improving the rates of BRCA mutation testing in patients with breast cancer as recommended by NCCN Guidelines. Proposals should address any barriers that are identified to routine BRCA mutation testing in patients with either early or metastatic breast cancer. Quality improvement projects can use any accepted methodology such as PDSA (Plan Do Study Act) cycles, root cause analysis, and other data-driven approaches. Proposals can include continuing education or training for health care professionals. They may be pilot projects or build on already existing pilot projects. 

ACCC will gather the outcomes data across all the projects with a goal of disseminating the results from the quality improvement projects to a larger audience. In order to gather consistent metrics across all projects, following notification of grant support, individual grantees will be contacted by ACCC to provide guidance on data collection for their project. Grantees will be required to capture and report this data back to ACCC at the end of the project. ACCC will have regular touch points with the individual grantees to monitor the progress of the projects. 

The intent of this RFP is to encourage organizations to submit Letters of Intent (LOIs) detailing concepts and ideas for projects aimed at increasing the rates of BRCA testing in appropriate patients with early or metastatic breast cancer and using these data to guide treatment selection, with the goal to improve patient outcomes. 

LOI Deadline: June 26, 2018 

Agency Website

Areas of Interest

Specific Areas of Interest:

1. Systems-based challenges related to ordering tests and communicating test results (For example, process improvement by integrating BRCA mutation testing into clinical pathways)

2. Access to genetic counselors

3. Turnaround time for BRCA mutation testing

4. Patient emotional needs, psychosocial support, and advocacy issues (For example, patient fear, patient concerns for future insurability following genetic testing)

5. Coordination of care within the multidisciplinary cancer care team

Eligibility Requirements

Applicant Eligibility Criteria: ACCC member community hospital-based programs and physician group practices



Amount Description

Individual projects requesting up to $150,000 will be considered.

Funding Type





Curriculum Development
Medical - Basic Science
Medical - Clinical Science
Medical - Translational
Social Sciences

External Deadline

June 26, 2018